X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=079074
https://www.nationaltribune.com.au/pfizer-s-covid-19-oral-anti-viral-available-to-more-australians-on-the-pharmaceutical-benefits-scheme-from-1-july/
https://www.ema.europa.eu/en/documents/overview/paxlovid-epar-medicine-overview_en.pdf
https://www.prnewswire.com/news-releases/ascletis-announces-entering-into-a-supply-agreement-of-ritonavir-tablets-with-simcere-301722875.html
https://www.pharmaceutical-technology.com/news/pfizer-paxlovid-global-fund/
https://www.outlookindia.com/business/zenara-pharma-launches-generic-of-paxlovid-for-covid-19-in-india-news-222189
https://www.globenewswire.com/news-release/2022/08/19/2501635/0/en/Sorrento-Therapeutics-Announces-China-National-Medical-Products-Administration-NMPA-IND-Clearance-of-STI-1558-An-Oral-Mpro-Inhibitor-for-Phase-I-Trial-In-COVID-19-Patients.html
https://www.globenewswire.com/news-release/2022/07/14/2480079/24825/en/Codexis-Announces-Agreement-with-Pfizer-to-Supply-Enzyme-for-the-Manufacture-of-PAXLOVID-nirmatrelvir-tablets-ritonavir-tablets.html
https://www.expresspharma.in/cipla-dndi-launch-4-in-1-antiretroviral-treatment-for-young-children-with-hiv-in-south-africa/
https://www.clinicaltrialsarena.com/news/junshis-covid-19-trial-endpoint/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203759
https://www.who.int/news/item/22-04-2022-who-recommends-highly-successful-covid-19-therapy-and-calls-for-wide-geographical-distribution-and-transparency-from-originator
https://www.prnewswire.com/news-releases/ascletis-announces-completion-of-first-sale-of-its-ritonavir-tablets-in-zhejiang-province-301516533.html
https://www.globenewswire.com/news-release/2022/04/04/2415684/0/en/Aligos-Therapeutics-Selects-Drug-Candidate-ALG-097558-a-Potent-Ritonavir-Free-Oral-Protease-Inhibitor-for-the-Treatment-and-Prevention-of-COVID-19-to-Advance-into-Development.html
https://www.prnewswire.com/news-releases/ascletis-announces-submission-of-marketing-authorization-application-for-ritonavir-in-hong-kong-301516242.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213857
https://www.prnewswire.com/news-releases/ascletis-announces-further-expansion-of-ritonavir-oral-tablet-production-capacity-to-530-million-tablets-per-year-301501432.html
https://www.pharmaceutical-technology.com/news/ascletis-marketing-authorisation-ritonavir/
https://www.biospectrumasia.com/news/25/19710/china-gives-conditional-approval-to-pfizers-oral-covid-19-drug.html
https://www.prnewswire.com/news-releases/ascletis-announces-submission-of-marketing-authorization-applications-for-ritonavir-in-multiple-european-countries-301481279.html
https://www.pharmaceutical-technology.com/news/australian-tga-two-oral-medicines-covid-19/
https://www.biospace.com/article/releases/ascletis-announces-signing-of-ritonavir-tablet-purchase-agreement-with-phokam-pharmaceutical-import-export-co-ltd-of-laos/?s=71
https://endpts.com/covid-19-roundup-ritonavir-production-to-reach-100m-doses-annually-schumer-calls-for-a-boost-to-domestic-vaccine-supply/
https://www.prnewswire.com/news-releases/ascletis-expands-ritonavir-oral-tablet-production-and-announces-oral-direct-acting-antiviral-pipeline-against-sars-cov-2-virus-301452489.html
https://www.expresspharma.in/us-fda-authorises-first-oral-antiviral-to-treat-covid/
https://www.europeanpharmaceuticalreview.com/news/166761/pfizers-paxlovid-can-be-used-for-the-treatment-of-covid-19-says-ema/
http://www.pharmafile.com/news/599802/pfizer-shares-efficacy-covid-pill-near-90-protection-against-hospitalisation
https://trialsitenews.com/pfizer-requests-emergency-use-authorization-for-oral-antiviral-paxlovid-ritonavir-to-treat-mild-to-moderate-covid-19/
https://www.fiercepharma.com/pharma/merck-molnupiravir-blockbuster-covid-19-pandemic-endemic-oral-antivirals-market
https://www.tga.gov.au/media-release/tga-grants-provisional-determination-pfizer-australias-covid-19-treatment-pf-07321332-ritonavir#:~:text=On%201%20October%202021%2C%20the,is%20an%20oral%20antiviral%20treatment.
https://www.fiercebiotech.com/biotech/pfizer-s-preventative-covid-19-oral-antiviral-gets-rolling-phase-2-3-trial
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091677
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-2-2021-1622637119.pdf
https://www.europeanpharmaceuticalreview.com/news/130708/repurposed-drugs-not-effective-treatment-for-hospitalised-covid-19-patients-who-says/
http://www.koreabiomed.com/news/articleView.html?idxno=9421
https://pharmaphorum.com/news/gileads-covid-19-drug-veklury-falls-short-in-whos-global-trial/
https://www.pharmaexcipients.com/news/ritanoivr-nanoamorphous-micellar-dispersion/
https://www.prnewswire.co.uk/news-releases/pharming-announces-enrolment-of-first-patient-in-multinational-clinical-trial-for-the-treatment-of-covid-19-with-ruconest-r--826834736.html
https://www.who.int/news-room/detail/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19
https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/antiviral-hyped-as-potential-covid-treatment-ineffective-finds-major-study/articleshow/76703597.cms
Market Place
Share 
